The International Osteoporosis Foundation (IOF) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) have presented ESCEO-IOF Young Investigator Awards to young investigators from 12 countries.
The prestigious Awards were presented on April 12th in Rome, Italy, on the occasion of the World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (WCO-IOF-ESCEO 2025).
IOF and ESCEO warmly congratulate the young investigators for their achievements and wish them continued success in their research and further career development.
The winning researchers are:
- Nadjia Amini, Belgium
- Zebadiah Boos, USA
- Fanny Buckinx, Belgium
- Mihai Costachescu, Romania
- Justine Demeuse, Belgium
- Simone Donati, Italy
- Atthakorn Jarusriwanna, Thailand
- Laurence Lapauw, Belgium
- Faidra Laskou, UK
- Sarra Mhamdi, Tunisia
- Kieran Mullen, USA
- Tu Thai Bao Nguyen, Vietnam
- Oluwabori Olukoyejo, Nigeria
- Maria Clara Ospino Guerra, Colombia
- Maelle Scouvemont, Belgium
- Nurdan Şentürk Durmuş, Turquie
- Marc Sim, Australia
- Sophie Van Heden, Belgium
- Leo Westbury, UK
###
About the World Congress on Osteoporosis, Osteoarthritis & Musculoskeletal Diseases (WCO-IOF-ESCEO)
Held jointly by IOF and ESCEO, the WCO-IOF-ESCEO annual congress is the world’s largest forum for the presentation of clinical research and new advances in the prevention and management of musculoskeletal disorders, including osteoporosis, osteoarthritis, sarcopenia, and frailty. The WCO-IOF-ESCEO 2025 is being held from April 10 -13, 2025, in Rome, Italy. For complete information, visit, www.wco-iof-esceo.org/
The next WCO-IOF-ESCO is planned from April 16-19, 2026 in Prague, Czech Republic.
About ESCEO
The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) is a non-profit organization, dedicated to a close interaction between clinical scientists dealing with rheumatic disorders, pharmaceutical industry developing new compounds in this field, regulators responsible for the registration of such drugs and health policymakers, to integrate the management of osteoporosis and osteoarthritis within the comprehensive perspective of health resources utilization. The objective of ESCEO is to provide practitioners with the latest clinical and economic information, allowing them to organize their daily practice, in an evidence-based medicine perspective, with a cost-conscious perception. www.esceo.org/
About IOF
The International Osteoporosis Foundation (IOF) is the world's largest nongovernmental organization dedicated to the prevention, diagnosis and treatment of osteoporosis and related musculoskeletal diseases. IOF’s network includes membership committees comprised of scientific experts, 340 patient, medical societies and universities in more than 100 countries, as well as over 1100 Fracture Liaison Services in all regions of the world. The IOF network is united in its mission to prioritize bone health and fracture prevention, striving toward a shared vision of a world free from fragility fractures, where healthy mobility is a reality for all. @iofbonehealth
Websites: www.osteoporosis.foundation ; www.capturethefracture.org ; www.worldosteoporosisday.org ; www.buildbetterbones.org